Company news
PharmaEssentia Corp. news in 2025
PharmaEssentia Corp.'s news releases, calls and decks from 2025, newest first.
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
December 24, 2025
PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
December 15, 2025
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in the Lancet Haematology
November 25, 2025
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
November 24, 2025
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
November 10, 2025
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
August 18, 2025
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
June 3, 2025
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
May 20, 2025
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
March 4, 2025
PharmaEssentia Corp. - ICC Arbitral Tribunal rules in favor of AOP Health in arbitration proceedings pertaining to BESREMi
February 18, 2025
CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
January 6, 2025
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges
January 2, 2025